99% Purity Rapamycin Sirolimus Raw Material Sirolimus Rapamycin Powder Rapamycin

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Rapamycin
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Rapamycin
• Name: Rapamycin Powder
• Appearance: White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 53123-88-9
• Mf: C51h79no13
• MW: 914.17186
• Density: 1.182
• Melting Point: 183-185 C
• Boiling Point: 973.017 C at 760 Mmhg
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 1 Ton/Month

Product Description

99% Purity Rapamycin Sirolimus Raw Material Sirolimus Rapamycin Powder Rapamycin

 

Product Description

Product Details

Product Name	Rapamycin
CAS No.	53123-88-9
MF	C51H79NO13
MW	914.17186
Appearance and shape	White powder

Rapamycin (Rapa, or Sirolimus) is a new form of macrolide immunosuppressive agent.    It is a white solid crystal.    Its melting point is 183-185ºC and it is lipophilic.    It is soluble in me-thanol, ethanol, chloro-form, and other organic solvents, very slightly soluble in water, and almost insoluble in ether.    It was first discovered in 1975 on the Chilean Easter Island as a secondary metabolite secreted by soil Streptomyces, and its chemical structure is that of a three-polyene macrolide compound.
Rapamycin (also known as Sirolimus) is macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus isolated from soil samples from Easter Island.    Rapamycin is an antifungal agent with immunosuppressive properties.    Rapamycin has antirejection properties without the side effects associated with other antirejection agents.    Rapamycin binds to a specific protein, Target of Rapamycin (TOR).    TOR is serine/threonine kinase.    TOR (mTOR) forms two major complexes: mTORC1,and mTORC2.    The mTORC1 consists of mTOR, Raptor, mLST8, FKBP38, PRAS40, and Deptor, and through specific binding of rapamycin to FKBP12, rapamycin inhibits the activity of mTORC1 leading to a decrease in protein synthesis, increased autophagy and inhibition of cell growth.

Application & Function

Rapamycin is a new form of immunosuppressive agent with good curative effects, low toxicity, and no nephrotoxicity.    It can be used to maintain the immunity of transplant organs (especially in kidney transplants) to alleviate immunological rejections after organ transplant surgeries.    The latest research has shown that Rapamycin can also be used to treat Alzheimer's.    When used on afflicted lab rats, it had a memory-restoring effect.    Rapamycin oral tablets can be taken with grapefruit juice to treat melanoma (a type of benign tumor common among Western populations), dramatically increase other chemotherapy drugs' anticancer effects, and extend patient survival.    Rapamycin is a mammalian target of rapamycin (mTOR) targeting inhibitor, which can treat tumors that are related to this pathway including kidney cancer, lymphoma, lung cancer, liver cancer, breast cancer, neuroendocrine carcinoma, gastric cancer, etc.    Its curative effects are especially strong for the rare diseases LAM (lymphangiomyomatosis) and TSC (tuberous sclerosis).
As an mTOR inhibitor, Sirolimus has a wide range of activities and has been shown to inhibit inflammation, proliferation, angiogenesis, fibrosis, and hyperpermeability.    Sirolimus is currently used in a variety of ways to prevent organ transplant rejection and has recently been used to treat advanced renal cell carcinoma.    Sirolimus-eluting heart stents have been shown to limit the rate of tissue overgrowth, thereby preventing coronary restenosis.    Early research suggests it could be an effective drug to control severe uveitis and may also play a role in treating age-related macular degeneration.

Specification